Diagnostic value of serum human epididymis protein 4 in human epithelial ovarian cancer: A meta-analysis

Chinese Journal of Clinical Oncology

Volumn 38, Issue 24, 2011, Pages 1559-1564

  Zhu, Yafei ^a   Gao, Guolan ^b   Huang, Qingshui ^a   Tang, Jun ^a  

^a NANCHANG UNIVERSITY   (China)

^b Beijing Aviation Hospital   (China)

Author keywords

Diagnostic test; Human epididymal secretory protein E4; Meta analysis; Ovarian cancer

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4;

AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EMBASE; FEMALE; HUMAN; MEDLINE; META ANALYSIS; OVARY CANCER; PROTEIN BLOOD LEVEL; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84863184000     PISSN: 10008179     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2011.24.021     Document Type: Article

References (33)

1. Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer[J]. Gynecol Oncol, 2010,116(3):378-383.
2. Drapkin R, von HHH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas[J]. Cancer Res,2005,65(6):2162-2169.
3. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma[J]. Cancer Res, 2003,63(13):3695-3700. (Pubitemid 36793054)
4. Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm[J]. Br J Cancer, 2011,104(5):863-670.
5. Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting[J]. Gynecol Oncol, 2011,121(3):487-491.
6. Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125[J]. Cancer Epidemiol Biomarkers Prev, 2009,18(5):1365-1372.
7. Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass[J]. Gynecol Oncol, 2010,117(3):440-445.
8. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008,108(2):402-408. (Pubitemid 351174295)
9. Abdel-Azeez HA, Labib HA, Sharaf SM, et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses[J]. Asian Pac J Cancer Prev, 2010,11(1):111-116.
10. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts[J]. Br J Cancer, 2009,100(8):1315-1319.
11. Kim YM, Whang DH, ParkJ, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case - control study in a Korean population[J]. Clin Chem Lab Med, 2011,49(3):527-534.
12. Park Y, Kim Y, Lee EY, et al. Reference ranges for HE4 and CA125 in a large asian population by automated assays and diagnostic performances for ovarian cancer[J]. Int J Cancer. 2011 Apr 11. doi: 10.1002/ijc.26129. [Epub ahead of print]. 130(5):1136-1144.